The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Nurix Licenses Drug Discovery Program to Sanofi Targeting Novel Transcription Factor for Autoimmune Diseases
Apr 02, 2025•about 1 year ago
Contract Type
agreement
San FranciscoOtherBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma
Description
Nurix Therapeutics, Inc. has exclusively licensed an undisclosed program targeting a previously undruggable transcription factor for autoimmune diseases to Sanofi. This program aims to address a central regulator of inflammation response in autoimmune diseases through targeted protein degradation, providing an innovative treatment option.
Company Information
Company
Nurix Therapeutics
Location
San Francisco, California, United States
About
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases. The company is focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases.
San FranciscoOtherBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma